TW202334201A - 抗Ｔａｕ抗體之組成物、劑型及方法 - Google Patents

抗Ｔａｕ抗體之組成物、劑型及方法 Download PDF

Info

Publication number
TW202334201A
TW202334201A TW111142044A TW111142044A TW202334201A TW 202334201 A TW202334201 A TW 202334201A TW 111142044 A TW111142044 A TW 111142044A TW 111142044 A TW111142044 A TW 111142044A TW 202334201 A TW202334201 A TW 202334201A
Authority
TW
Taiwan
Prior art keywords
antibody
tau
tauopathy
dose
treating
Prior art date
Application number
TW111142044A
Other languages
English (en)
Chinese (zh)
Inventor
拉里薩 瑞德曼
Original Assignee
日商衛材R&D企管股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商衛材R&D企管股份有限公司 filed Critical 日商衛材R&D企管股份有限公司
Publication of TW202334201A publication Critical patent/TW202334201A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111142044A 2021-11-03 2022-11-03 抗Ｔａｕ抗體之組成物、劑型及方法 TW202334201A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163275045P 2021-11-03 2021-11-03
US63/275,045 2021-11-03
US202163290278P 2021-12-16 2021-12-16
US63/290,278 2021-12-16
US202263316582P 2022-03-04 2022-03-04
US202263316616P 2022-03-04 2022-03-04
US63/316,582 2022-03-04
US63/316,616 2022-03-04

Publications (1)

Publication Number Publication Date
TW202334201A true TW202334201A (zh) 2023-09-01

Family

ID=84360026

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142044A TW202334201A (zh) 2021-11-03 2022-11-03 抗Ｔａｕ抗體之組成物、劑型及方法

Country Status (9)

Country Link
US (1) US20260159575A1 (enExample)
EP (1) EP4426336A1 (enExample)
JP (1) JP2024540226A (enExample)
KR (1) KR20240118915A (enExample)
AU (1) AU2022381556A1 (enExample)
CA (1) CA3237660A1 (enExample)
MX (1) MX2024005430A (enExample)
TW (1) TW202334201A (enExample)
WO (1) WO2023079485A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
CN117946264B (zh) * 2024-03-21 2024-06-04 江西赛基生物技术有限公司 一种抗Tau蛋白单克隆抗体及其应用
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
EP3551220B1 (en) * 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Also Published As

Publication number Publication date
KR20240118915A (ko) 2024-08-05
WO2023079485A1 (en) 2023-05-11
CA3237660A1 (en) 2023-05-11
MX2024005430A (es) 2024-05-21
JP2024540226A (ja) 2024-10-31
EP4426336A1 (en) 2024-09-11
AU2022381556A1 (en) 2024-05-02
US20260159575A1 (en) 2026-06-11

Similar Documents

Publication Publication Date Title
WO2023095852A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
KR20240118915A (ko) 항-타우 항체 조성물, 투여 형태 및 방법
JP2025508757A (ja) 抗ｔｒｅｍ２抗体の使用方法
TW202434633A (zh) 治療甲狀腺眼疾之方法
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
WO2023111618A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20240352109A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
IL298711A (en) Antibodies that bind tgf-alpha and epiregulin for use in the treatment of pain
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
CN118215497A (zh) 抗tau抗体组合物、剂型和方法
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
HK40107811A (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
US20190247503A1 (en) Methods for treating relapsing forms of multiple sclerosis